WntResearch announced that the company has filed a new patent application that broadly covers the use of Foxy-5 in the treatment of Acute Myeloid Leukemia (AML). In a research exchange with a Brazilian research group at the Hematology and Transfusion Medicine Center at University of Campinas/Hemocentro-UNICAMP in São Paulo, WNT Research has provided Foxy-5 and expertise of its use in the experimental studies. In exchange the company has secured that all intellectual property rights accrue WNTResearch based on the research group's research with Foxy-5 on AML cells. The research group has concluded that Foxy-5, by restoring WNT5a levels, could represent a strategy to counterbalance several oncogenic processes present in leukemia by inhibiting cell growth. Thus, Foxy-5 treatment may be an important approach to impair AML growth and maintenance and arises as a promising therapeutic target.